Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

Recent & Breaking News (TSX:VRX)

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  August 29, 2017

What's The FDA Saying About Valeant's Manufacturing Facility Issues?

Benzinga.com  August 21, 2017

Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility

PR Newswire August 16, 2017

Watch These 4 Huge Put Purchases In Monday Trade

Benzinga.com  August 14, 2017

Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy

PR Newswire August 9, 2017

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 8, 2017

Valeant Announces Second-Quarter 2017 Results

PR Newswire August 8, 2017

Investor Network: Valeant Pharmaceuticals International Inc to Host Earnings Call

Accesswire August 8, 2017

Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA

PR Newswire August 7, 2017

August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Benzinga.com  August 1, 2017

EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery

GlobeNewswire August 1, 2017

Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

PR Newswire July 27, 2017

Pharming Reports on Financial Results for the First Half of 2017

PR Newswire Europe Non Regulatory July 27, 2017

Daily Technical Summary Reports on Healthcare Stocks -- Valeant Pharma, Palatin Technologies, AMAG Pharma, and IDEXX Labs

PR Newswire July 24, 2017

A Peek Into The Markets: U.S. Stock Futures Edge Higher; Netflix Earnings In Focus

Benzinga.com  July 17, 2017

Valeant Agrees To Sell Obagi Medical Products Business

PR Newswire July 17, 2017

S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices

Canada NewsWire July 14, 2017

Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018

PR Newswire July 13, 2017

Valeant Announces Q2 2017 Financial Results Date And Conference Call Details

PR Newswire July 10, 2017

Valeant Pays Down $811 Million of Senior Secured Term Loans

PR Newswire July 10, 2017